CL2004000257A1 - Compuestos heterociclil-3-sulfonilaza-indol o -indazol; su composicion farmaceutica; su procedimiento de preparacion; y su uso en el tratamiento de trastornos por deficit atencional, abstinencia producto de la adiccion a drogas, alcohol o nicotina, e - Google Patents
Compuestos heterociclil-3-sulfonilaza-indol o -indazol; su composicion farmaceutica; su procedimiento de preparacion; y su uso en el tratamiento de trastornos por deficit atencional, abstinencia producto de la adiccion a drogas, alcohol o nicotina, eInfo
- Publication number
- CL2004000257A1 CL2004000257A1 CL200400257A CL2004000257A CL2004000257A1 CL 2004000257 A1 CL2004000257 A1 CL 2004000257A1 CL 200400257 A CL200400257 A CL 200400257A CL 2004000257 A CL2004000257 A CL 2004000257A CL 2004000257 A1 CL2004000257 A1 CL 2004000257A1
- Authority
- CL
- Chile
- Prior art keywords
- treatment
- sulfonilaza
- heterociclil
- abstinence
- addiction
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
LA PRESENTE INVENCION PROPORCIONA UN COMPUESTO DE FORMULA (I) Y SU USO PARA EL TRATAMIENTO DE UN TRANSTORNO DEL SISTEMA NERVIOSO CENTRAL RELACIONADO CON, O AFECTADO POR EL RECEPTORTR 5-HT6.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US44751503P | 2003-02-14 | 2003-02-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2004000257A1 true CL2004000257A1 (es) | 2005-01-14 |
Family
ID=32908450
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL200400257A CL2004000257A1 (es) | 2003-02-14 | 2004-02-12 | Compuestos heterociclil-3-sulfonilaza-indol o -indazol; su composicion farmaceutica; su procedimiento de preparacion; y su uso en el tratamiento de trastornos por deficit atencional, abstinencia producto de la adiccion a drogas, alcohol o nicotina, e |
Country Status (12)
Country | Link |
---|---|
US (2) | US7259165B2 (es) |
EP (1) | EP1592690A1 (es) |
JP (1) | JP2006517966A (es) |
CN (1) | CN100482662C (es) |
AR (1) | AR043180A1 (es) |
AU (1) | AU2004213375A1 (es) |
BR (1) | BRPI0407493A (es) |
CA (1) | CA2515571A1 (es) |
CL (1) | CL2004000257A1 (es) |
MX (1) | MXPA05008441A (es) |
TW (1) | TW200418830A (es) |
WO (1) | WO2004074286A1 (es) |
Families Citing this family (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0117396D0 (en) * | 2001-07-17 | 2001-09-05 | Glaxo Group Ltd | Chemical compounds |
US7528165B2 (en) | 2001-12-13 | 2009-05-05 | National Health Research Institutes | Indole compounds |
US7632955B2 (en) * | 2001-12-13 | 2009-12-15 | National Health Research Institutes | Indole compounds |
ATE398108T1 (de) * | 2002-03-27 | 2008-07-15 | Glaxo Group Ltd | Chinolinderivate und deren verwendung als 5-ht6 liganden |
WO2003080608A2 (en) * | 2002-03-27 | 2003-10-02 | Glaxo Group Limited | Quinoline and aza-indole derivatives and their use as 5-ht6 ligands |
CA2515570A1 (en) * | 2003-02-14 | 2004-09-02 | Wyeth | Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands |
US20040204422A1 (en) * | 2003-04-14 | 2004-10-14 | Abbott Gmbh & Co. Kg. | N-[(Piperazinyl)hetaryl]arylsulfonamide compounds |
ES2258760T3 (es) | 2003-07-22 | 2006-09-01 | Arena Pharmaceuticals, Inc. | Derivados de diaril y de la urea de arileteroaril usados como moduladores del receptor de la serotonina 5-ht2a utiles para la profilaxis y el tratamiento de desordenes a ellos asociados. |
CA2550361C (en) | 2003-12-19 | 2014-04-29 | Prabha Ibrahim | Compounds and methods for development of ret modulators |
US20070066641A1 (en) * | 2003-12-19 | 2007-03-22 | Prabha Ibrahim | Compounds and methods for development of RET modulators |
PT1753764E (pt) | 2004-06-09 | 2009-01-28 | Glaxo Group Ltd | Derivados de pirrolopiridina |
US7498342B2 (en) | 2004-06-17 | 2009-03-03 | Plexxikon, Inc. | Compounds modulating c-kit activity |
US7626021B2 (en) | 2004-07-27 | 2009-12-01 | Sgx Pharmaceuticals, Inc. | Fused ring heterocycle kinase modulators |
SG156685A1 (en) * | 2004-07-27 | 2009-11-26 | Sgx Pharmaceuticals Inc | Fused ring heterocycle kinase modulators |
WO2006062481A1 (en) * | 2004-12-09 | 2006-06-15 | Biovitrum Ab | New benzofuran derivatives and their use in the treatment of obesity, type ii diabetes and cns disorders . |
US7456289B2 (en) * | 2004-12-31 | 2008-11-25 | National Health Research Institutes | Anti-tumor compounds |
GB2422831A (en) * | 2005-02-04 | 2006-08-09 | Oxagen Ltd | Pyrrolopyridines and their use in the treatment of diseases mediated by PGD2 at the CRTH2 receptor |
GB2422830A (en) * | 2005-02-04 | 2006-08-09 | Oxagen Ltd | Pyrrolopyridines and their use in the treatment of diseases mediated by PGD2 at the CRTH2 receptor |
GB2422829A (en) * | 2005-02-04 | 2006-08-09 | Oxagen Ltd | Pyrrolopyridines and their use in the treatment of diseases mediated by PGD2 at the CRTH2 receptor |
JP2008545652A (ja) | 2005-05-17 | 2008-12-18 | プレキシコン,インコーポレーテッド | c−kitおよびc−fms活性を調節する化合物およびその用途 |
CA2609126A1 (en) * | 2005-05-20 | 2006-11-30 | Vertex Pharmaceuticals Incorporated | Pyrrolopyridines useful as inhibitors of protein kinase |
NZ565255A (en) | 2005-06-22 | 2010-04-30 | Plexxikon Inc | Pyrrolo[2,3-b] pyridine derivatives as protein kinase inhibitors |
CA2618165A1 (en) * | 2005-08-09 | 2007-02-15 | Glaxo Group Limited | Imidazopyridine derivatives as cannabinoid receptor ligands |
WO2007021711A2 (en) * | 2005-08-15 | 2007-02-22 | Wyeth | Substituted-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands |
CN101305010A (zh) * | 2005-09-01 | 2008-11-12 | 阿雷生物药品公司 | Raf抑制剂化合物及其用法 |
WO2007031838A1 (en) | 2005-09-16 | 2007-03-22 | Ranbaxy Laboratories Limited | Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors |
US20100022571A1 (en) * | 2005-09-16 | 2010-01-28 | Palle Venkata P | Substituted pyrazolo [3,4-b]pyridines as phosphodiesterase inhibitors |
ATE449776T1 (de) * | 2005-12-15 | 2009-12-15 | Hoffmann La Roche | Pyrroloä2,3-cüpyridinderivate |
US7645752B2 (en) * | 2006-01-13 | 2010-01-12 | Wyeth Llc | Sulfonyl substituted 1H-indoles as ligands for the 5-hydroxytryptamine receptors |
KR20090006148A (ko) * | 2006-04-05 | 2009-01-14 | 와이어쓰 | 5-히드록시트립타민-6 리간드로서의 설포닐-3-헤테로시클릴인다졸 유도체 |
WO2007120596A1 (en) * | 2006-04-12 | 2007-10-25 | Wyeth | DIHYDRO[1,4]DIOXINO[2,3-e]INDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS |
MX2008013206A (es) * | 2006-04-19 | 2008-10-22 | Abbott Gmbh & Co Kg | Compuestos heterociclicos adecuados para el tratamiento de trastornos que responden a modulacion del receptor de serotonina 5ht6. |
WO2008063888A2 (en) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
WO2008079909A1 (en) | 2006-12-21 | 2008-07-03 | Plexxikon, Inc. | Pyrrolo [2,3-b] pyridines as kinase modulators |
US7872018B2 (en) | 2006-12-21 | 2011-01-18 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
PE20081581A1 (es) | 2006-12-21 | 2008-11-12 | Plexxikon Inc | COMPUESTOS PIRROLO[2,3-b]PIRIDINAS COMO MODULADORES DE QUINASA |
EP2120950B1 (en) * | 2007-03-21 | 2012-07-04 | Glaxo Group Limited | Use of quinoline derivatives in the treatment of pain |
US20100190777A1 (en) | 2007-07-17 | 2010-07-29 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
EP2254564A1 (en) | 2007-12-12 | 2010-12-01 | Glaxo Group Limited | Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline |
WO2009123714A2 (en) | 2008-04-02 | 2009-10-08 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor |
US9126946B2 (en) | 2008-10-28 | 2015-09-08 | Arena Pharmaceuticals, Inc. | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto |
EP2414356B1 (en) | 2009-04-03 | 2015-09-02 | F.Hoffmann-La Roche Ag | Propane-i-sulfonic acid {3-[5-(4-chloro-phenyl)-1h-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide compositions and uses thereof |
US8329724B2 (en) | 2009-08-03 | 2012-12-11 | Hoffmann-La Roche Inc. | Process for the manufacture of pharmaceutically active compounds |
MX2012005284A (es) | 2009-11-06 | 2012-06-28 | Plexxikon Inc | Compuestos y metodos para la modulacion de cinasas. e indicaciones para ello. |
CA2797281A1 (en) * | 2010-05-06 | 2011-11-10 | Merck Sharp & Dohme Corp. | Aza-indole derivatives useful as modulators of faah |
AU2012214762B2 (en) | 2011-02-07 | 2015-08-13 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
TWI558702B (zh) | 2011-02-21 | 2016-11-21 | 普雷辛肯公司 | 醫藥活性物質的固態形式 |
US9150570B2 (en) | 2012-05-31 | 2015-10-06 | Plexxikon Inc. | Synthesis of heterocyclic compounds |
CN103613591B (zh) * | 2012-09-29 | 2016-04-13 | 上海科州药物研发有限公司 | 作为cMet抑制剂的化合物及其制备方法和用途 |
CN104230922B (zh) * | 2013-06-19 | 2016-12-28 | 中国科学院上海药物研究所 | 一类五元杂环并吡啶类化合物及其制备方法和用途 |
US9446978B2 (en) | 2014-02-14 | 2016-09-20 | Charles Douglas Spitler | System and method for continuous strand fiberglass media processing |
US10106452B2 (en) | 2014-02-14 | 2018-10-23 | Superior Fibers, Llc | System and method of continuous glass filament manufacture |
US10351462B1 (en) | 2014-02-14 | 2019-07-16 | Superior Fibers, Llc | Method of manufacturing fiberglass filtration media |
US9580416B2 (en) | 2014-07-02 | 2017-02-28 | Pharmacyclics Llc | Inhibitors of Bruton's tyrosine kinase |
SG11201610407QA (en) | 2014-07-08 | 2017-01-27 | Sunshine Lake Pharma Co Ltd | Aromatic heterocyclic derivatives and pharmaceutical applications thereof |
WO2016160613A1 (en) | 2015-03-27 | 2016-10-06 | Spitler Charles Douglas | Skin stiffness characteristics and loft control production system and method with variable moisture content in input fiberglass |
KR20180022792A (ko) | 2015-06-12 | 2018-03-06 | 엑소반트 사이언시즈 게엠베하 | 렘 수면 행동 장애의 예방 및 치료에 유용한 디아릴 및 아릴헤테로아릴 우레아 유도체 |
EP3322415A4 (en) | 2015-07-15 | 2019-03-13 | Axovant Sciences GmbH | ARYLHERETOARYL UREA DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONINERGIC RECEPTOR USEFUL FOR THE PROPHYLAXIS AND TREATMENT OF HALLUCINATIONS ASSOCIATED WITH NEURODEGENERATIVE DISEASE |
WO2018049191A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyridone derivatives as hpk1 modulators and uses thereof for the treatment of cancer |
US10266530B2 (en) | 2016-09-09 | 2019-04-23 | Incyte Corporation | Pyrazolopyridine compounds and uses thereof |
TW201811799A (zh) | 2016-09-09 | 2018-04-01 | 美商英塞特公司 | 吡唑并嘧啶化合物及其用途 |
WO2018049214A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer |
US20180228786A1 (en) | 2017-02-15 | 2018-08-16 | Incyte Corporation | Pyrazolopyridine compounds and uses thereof |
WO2019051199A1 (en) | 2017-09-08 | 2019-03-14 | Incyte Corporation | 6-CYANO-INDAZOLE COMPOUNDS AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) MODULATORS |
US10745388B2 (en) | 2018-02-20 | 2020-08-18 | Incyte Corporation | Indazole compounds and uses thereof |
US10752635B2 (en) | 2018-02-20 | 2020-08-25 | Incyte Corporation | Indazole compounds and uses thereof |
LT3755703T (lt) | 2018-02-20 | 2022-10-10 | Incyte Corporation | N-(fenil)-2-(fenil)pirimidin-4-karboksamido dariniai ir susiję junginiai, kaip hpk1 inhibitoriai, skirti vėžio gydymui |
US11299473B2 (en) | 2018-04-13 | 2022-04-12 | Incyte Corporation | Benzimidazole and indole compounds and uses thereof |
US10899755B2 (en) | 2018-08-08 | 2021-01-26 | Incyte Corporation | Benzothiazole compounds and uses thereof |
JP7399968B2 (ja) | 2018-09-25 | 2023-12-18 | インサイト・コーポレイション | Alk2及び/またはfgfr調節剤としてのピラゾロ[4,3-d]ピリミジン化合物 |
US11066394B2 (en) | 2019-08-06 | 2021-07-20 | Incyte Corporation | Solid forms of an HPK1 inhibitor |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1289479C (zh) | 1996-11-26 | 2006-12-13 | Nps艾里利克斯有限公司 | 作为5-ht1d受体配位体的5-环吲哚化合物 |
US6194410B1 (en) * | 1998-03-11 | 2001-02-27 | Hoffman-La Roche Inc. | Pyrazolopyrimidine and pyrazolines and process for preparation thereof |
MXPA01010655A (es) | 1999-04-21 | 2002-11-04 | Allelix Biopharma | Compuestos de piperidin-indol que tienen afinidad por 5-ht6. |
DE60011269T2 (de) * | 1999-08-12 | 2005-06-23 | Nps Allelix Corp., Mississauga | Azaidole mit serotonin rezeptor affinität |
BR0114552A (pt) * | 2000-10-20 | 2003-07-01 | Biovitrum Ab | N1- (benzenosulfonil) indóis 2-,3-,4-, 5- substituìdos e seu uso em terapia |
ES2264994T3 (es) * | 2000-12-22 | 2007-02-01 | Wyeth | Compuestos heterociclilalquilindol o -azaindol como ligandos de 5-hidroxitriptamina-6. |
KR100600240B1 (ko) * | 2001-06-07 | 2006-07-13 | 에프. 호프만-라 로슈 아게 | 5-ht6 수용체 친화도를 갖는 신규한 인돌 유도체 |
EP1414442A1 (en) * | 2001-08-07 | 2004-05-06 | Smithkline Beecham Plc | 3-arylsulfonyl-7-piperazinyl- indoles, -benzofurans and -benzothiophenes with 5-ht6 receptor affinity for treating cns disorders |
ATE398108T1 (de) | 2002-03-27 | 2008-07-15 | Glaxo Group Ltd | Chinolinderivate und deren verwendung als 5-ht6 liganden |
WO2003080608A2 (en) * | 2002-03-27 | 2003-10-02 | Glaxo Group Limited | Quinoline and aza-indole derivatives and their use as 5-ht6 ligands |
UA78999C2 (en) * | 2002-06-04 | 2007-05-10 | Wyeth Corp | 1-(aminoalkyl)-3-sulfonylazaindoles as ligands of 5-hydroxytryptamine-6 |
TW200403243A (en) * | 2002-07-18 | 2004-03-01 | Wyeth Corp | 1-Heterocyclylalkyl-3-sulfonylazaindole or-azaindazole derivatives as 5-hydroxytryptamine-6 ligands |
-
2004
- 2004-02-10 CA CA002515571A patent/CA2515571A1/en not_active Abandoned
- 2004-02-10 WO PCT/US2004/003930 patent/WO2004074286A1/en active Application Filing
- 2004-02-10 MX MXPA05008441A patent/MXPA05008441A/es active IP Right Grant
- 2004-02-10 TW TW093103030A patent/TW200418830A/zh unknown
- 2004-02-10 JP JP2006503469A patent/JP2006517966A/ja active Pending
- 2004-02-10 AU AU2004213375A patent/AU2004213375A1/en not_active Withdrawn
- 2004-02-10 CN CNB2004800096051A patent/CN100482662C/zh not_active Expired - Fee Related
- 2004-02-10 BR BRPI0407493-9A patent/BRPI0407493A/pt not_active IP Right Cessation
- 2004-02-10 EP EP04709917A patent/EP1592690A1/en not_active Withdrawn
- 2004-02-12 CL CL200400257A patent/CL2004000257A1/es unknown
- 2004-02-13 AR ARP040100458A patent/AR043180A1/es unknown
- 2004-02-13 US US10/778,441 patent/US7259165B2/en not_active Expired - Fee Related
-
2007
- 2007-06-19 US US11/820,565 patent/US7576087B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
MXPA05008441A (es) | 2005-10-19 |
EP1592690A1 (en) | 2005-11-09 |
US20080015201A1 (en) | 2008-01-17 |
US7576087B2 (en) | 2009-08-18 |
US7259165B2 (en) | 2007-08-21 |
BRPI0407493A (pt) | 2006-02-14 |
AU2004213375A1 (en) | 2004-09-02 |
JP2006517966A (ja) | 2006-08-03 |
US20040167030A1 (en) | 2004-08-26 |
CA2515571A1 (en) | 2004-09-02 |
AR043180A1 (es) | 2005-07-20 |
WO2004074286A1 (en) | 2004-09-02 |
CN100482662C (zh) | 2009-04-29 |
TW200418830A (en) | 2004-10-01 |
CN1777602A (zh) | 2006-05-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2004000257A1 (es) | Compuestos heterociclil-3-sulfonilaza-indol o -indazol; su composicion farmaceutica; su procedimiento de preparacion; y su uso en el tratamiento de trastornos por deficit atencional, abstinencia producto de la adiccion a drogas, alcohol o nicotina, e | |
SE0301700D0 (sv) | Novel compounds | |
BRPI0619153B8 (pt) | derivados de 4-amino-pirroltriazina substituída, e composição farmacêutica | |
MY142067A (en) | Xanthine derivatives as selective hm74a agonists, processes for the manufacture of said derivatives, formulations comprising these derivatives, and their use in the treatment of diseases where under-activation of the hm74a receptor contributes to the disease | |
UY29796A1 (es) | Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor | |
JO2686B1 (en) | Vehicles | |
SG135192A1 (en) | Substituted pyrazoline compounds, their preparation and use as medicaments | |
ECSP066391A (es) | [1,8] naftiridin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia | |
CL2009000349A1 (es) | Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer. | |
MA29088B1 (fr) | Composes d'indazole-carboxamide. | |
ES2340502T3 (es) | Compuestos de 1,4,8-triazaespiro(4,5)decan-2-ona sustituidos para el tratamiento de la obesidad. | |
UY27983A1 (es) | Nuevos compuestos de isotiazol e isoxazol como inhibidores del factor de crecimiento transformador (tgf) | |
ATE441646T1 (de) | 5-ht4-rezeptoragonistenverbindungen | |
AR054252A1 (es) | Composicion farmaceutica oral que contiene sales de ditosilato de 4-quinazolinamina | |
ATE431824T1 (de) | Chinolinon-carboxamid-verbindungen | |
TW200745043A (en) | Substituted pyrazoline compounds, their preparation and use as medicaments | |
EA200701356A1 (ru) | Ингибиторы транспорта глицина | |
BRPI0418099A (pt) | compostos, composição farmacêutica, e uso de um composto | |
UA104988C2 (uk) | Похідні піроніндолу та спосіб їх отримання | |
PL1654253T3 (pl) | Podstawione pochodne 3-pirolidynoindolu | |
BRPI0519198A2 (pt) | moduladores de delta-opiàide tricÍclicos | |
PL1853232T3 (pl) | Trwałe postaci krystaliczne mesylanu bifeprunoksu, postaci dawkowania oraz sposoby ich stosowania | |
UY27593A1 (es) | Nuevos compuestos | |
UA90504C2 (ru) | Лекарственное средство для лечения заболеваний дыхательных путей | |
UY29741A1 (es) | Sales de 1,5- diaril pirazol-3-carboxamidas, procesos de preparación, composeciones farmacéuticas que las contienen, aplicaciones y métodos de uso. |